ILMN

Business Context and Reporting Period

Company: ILLUMINA, INC.
Filing Type: Form 10-K (Annual Report)
Period Ended: January 2, 2005 (53-week fiscal year)
Business Overview: Illumina develops and markets next-generation tools for the large-scale analysis of genetic variation and function, primarily utilizing proprietary BeadArray and Oligator technologies. The company operates in a single business segment focused on SNP genotyping and gene expression profiling for life sciences and pharmaceutical research.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 80% to $50.6 million, driven primarily by a 120% increase in product revenue ($40.5 million) due to sales of BeadStations and consumables. Service revenue grew 24% to $8.1 million, largely attributed to the International HapMap Project.
• Profitability Improvement: Net loss narrowed significantly from $27.1 million to $6.2 million. This improvement was aided by a $4.2 million net gain from litigation settlements and judgments (reduction of a prior employment lawsuit liability and settlement with Applied Biosystems).
• Debt Elimination: The company eliminated all long-term debt ($25.2 million) in August 2004 following a sale-leaseback transaction of its San Diego facilities, which generated $15.5 million in net cash proceeds.
• Expense Trends: Selling, general, and administrative (SG&A) expenses increased 33% to $25.1 million due to expanded sales and marketing efforts. Research and development (R&D) expenses decreased 6% to $21.1 million.

Guidance, Outlook, and Risks

• Outlook: Management expects revenues to increase above 2004 levels in 2005, driven by new product launches (whole-genome genotyping and gene expression BeadChips) and the Invitrogen collaboration. However, revenue from the International HapMap Project is expected to decline as the grant concludes in early 2005.
• Profitability: The company expects to continue incurring net losses in the near term due to significant investments in R&D, manufacturing scale-up, and sales infrastructure. Adoption of SFAS 123R (Share-Based Payment) in July 2005 is expected to result in significant non-cash charges to operating expenses.
• Acquisitions: Signed a definitive agreement to acquire CyVera Corporation for $17.5 million (stock and liability assumption), expected to close by March 2005.
• Key Risks:
  • Litigation: Ongoing patent infringement lawsuit filed by Affymetrix in July 2004; an unfavorable outcome could materially harm operations.
  • Market Acceptance: Success depends on the adoption of new technologies in emerging markets for genetic analysis.
  • Liquidity: While current cash is sufficient for 24 months, future capital requirements may necessitate additional equity financing, which could be dilutive.
  • Personnel: Chief Financial Officer Timothy Kish intends to resign in Q2 2005.

Investor Verification Checklist

• HapMap Project Dependency: Verify the timeline for the completion of the International HapMap Project and the specific revenue exposure (approx. 30% of 2004 revenue) to ensure commercial products can offset the grant's conclusion.
• Affymetrix Litigation Status: Monitor the progress of the patent infringement suit filed by Affymetrix, as an injunction could block product sales.
• Product Mix Shift: Confirm the transition from high-value system sales (BeadLabs) to recurring consumable revenue and the success of new BeadChip launches in 2005.
• Stock-Based Compensation Impact: Assess the financial impact of adopting SFAS 123R in July 2005 on reported operating expenses and net loss.
• CyVera Integration: Track the closing of the CyVera acquisition and the timeline for integrating its digital-microbead platform into Illumina's product line.